PM
KURA icon

Prosight Management’s Kura Oncology KURA Stock Holding History

Prosight Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Sell
2,021,964
-1,334,736
-40% -$12.6M 3.82% 9
2026
Q1 		$27.3M Buy
3,356,700
+827,100
+33% +$7.11M 4.48% 9
2025
Q4 		$26.3M Sell
2,529,600
-228,916
-8% -$2.4M 5.43% 5
2025
Q3 		$24.4M Sell
2,758,516
-422,668
-13% -$3.01M 5.69% 4
2025
Q2 		$18.4M Buy
3,181,184
+1,102,869
+53% +$6.76M 4.48% 9
2025
Q1 		$13.7M Buy
2,078,315
+753,315
+57% +$5.87M 4.51% 7
2024
Q4 		$11.5M Buy
1,325,000
+619,891
+88% +$8.92M 3.19% 14
2024
Q3 		$13.8M Buy
705,109
+75,209
+12% +$1.52M 3.39% 11
2024
Q2 		$13M Sell
629,900
-330,100
-34% -$6.79M 3.88% 8
2024
Q1 		$20.5M Buy
960,000
+10,000
+1% +$194K 5.7% 5
2023
Q4 		$13.7M Sell
950,000
-982,456
-51% -$9.66M 5.48% 6
2023
Q3 		$17.6M Buy
1,932,456
+589,097
+44% +$5.98M 5.59% 5
2023
Q2 		$14.2M Buy
+1,343,359
New +$15.9M 4.16% 10
2020
Q4 		– Sell
-107,367
Closed -$3.29M – 50
2020
Q3 		$3.29M Sell
107,367
-577,633
-84% -$12.8M 1.56% 26
2020
Q2 		$11.2M Sell
685,000
-765,000
-53% -$11M 4.79% 4
2020
Q1 		$14.4M Buy
1,450,000
+414,000
+40% +$4.74M 6.74% 3
2019
Q4 		$14.2M Buy
1,036,000
+147,848
+17% +$2.19M 6.25% 4
2019
Q3 		$13.5M Buy
888,152
+20,342
+2% +$362K 7.47% 3
2019
Q2 		$17.1M Buy
867,810
+694,916
+402% +$11.5M 8.62% 3
2019
Q1 		$2.87M Sell
172,894
-143,687
-45% -$2.21M 1.25% 29
2018
Q4 		$4.45M Buy
316,581
+62,950
+25% +$834K 2.29% 18
2018
Q3 		$4.44M Sell
253,631
-34,256
-12% -$657K 2.48% 18
2018
Q2 		$5.24M Buy
+287,887
New +$4.88M 3.84% 14

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Prosight Management's KURA Position: Q2 2026 in Review

Prosight Management reduced its Kura Oncology (KURA) stake by 40% in Q2 2026, selling an estimated $12.6M and leaving 2,021,964 shares worth $22.2M. The position accounts for 3.82% of the portfolio, ranked #9.

Prosight Management first reported a position in KURA in Q2 2018 and has held it in 23 quarters since. The position peaked at $27.3M in Q1 2026. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Prosight Management held 2,021,964 shares of Kura Oncology worth $22.2M as of Q2 2026.
  • Prosight Management sold 1,334,736 Kura Oncology shares in Q2 2026, an estimated $12.6M.
  • Kura Oncology made up 3.82% of Prosight Management's portfolio in Q2 2026, its #9 holding.
  • Prosight Management first reported a position in Kura Oncology in Q2 2018 and has held it in 23 quarters since.
  • Prosight Management's Kura Oncology position peaked at $27.3M in Q1 2026.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.